Analystreport

CalAmp Corp. (NASDAQ: CAMP) was upgraded by analysts at Canaccord Genuity to a "buy" rating. They now have a $12.00 price target on the stock.

CAMP4 Therapeutics Corporation  (CAMP) 
Last camp4 therapeutics corporation earnings: 12/19 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.calamp.com/home/default.aspx